SEC Form 4 · accession 0001178913-17-001935
Artemis Therapeutics, Inc. · ATMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dana Wolf
Officer — Chief Scientific Officer
Period of report
Jun 26, 2017
Accepted (ET)
Jun 28, 2017 · 6:02 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 26, 2017 | M | 35,202 | $0.01 | A | 35,202 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.01 | Jun 26, 2017 | M | 35,202 | D | — | Aug 23, 2026 | Common Stock | 35,202 | 70,406 | D |
Explanation of responses
- F1The option, representing a right to purchase 105,608 shares of the Issuer's common stock at an exercise price of $0.01 per share, became exercisable as to 35,202 shares of common stock upon the date of grant (August 23, 2016) and 35,203 shares of common stock upon the one and two year anniversaries of the grant date, with the option becoming fully vested on August 23, 2018.